Results 111 to 120 of about 9,635 (207)

Evaluating Long-Term Effectiveness of Cystic Fibrosis Modulator Therapies after Rapid Adoption: A Dual-Approach Study. [PDF]

Ann Am Thorac Soc
Miranda Afonso P, Zhou GC, Su W, Burgel PR, Cromwell E, Goss CH, Keogh RH, Liou TG, Marshall BC, Mayer-Hamblett N, Morgan WJ, Ostrenga JS, Pasta DJ, Schechter MS, Stanojevic S, Wainwright CE, Szczesniak RD, Andrinopoulou ER.   +17 more
europepmc   +1 more source

Beyond BMI: Nutritional Recovery and Functional Implications of CFTR Modulators in Cystic Fibrosis. [PDF]

Biology (Basel)
Linguiti G, Granberg V, Leonetti G, Lassandro G, Lassandro M, Delvecchio M, Giordano P.   +6 more
europepmc   +1 more source

Post-marketing safety profile of lumacaftor/ivacaftor in cystic fibrosis treatment: a pharmacovigilance analysis based on FAERS. [PDF]

Front Med (Lausanne)
Wang T, Yang W, Luo Y, Zhan Y, Zou F, Cui Z, Lan Y.   +6 more
europepmc   +1 more source

Editorial: Real-world experience with CFTR modulator therapy

Frontiers in Pharmacology, 2023
Burkhard Tümmler, Burkhard Tümmler, Pierre-Régis Burgel, Pierre-Régis Burgel   +3 more
doaj   +1 more source

Correction to: Improved quality of life in cystic fibrosis patients observed up to 36 months after starting Elexacaftor/Tezacaftor/Ivacaftor treatment. [PDF]

J Patient Rep Outcomes
Buniotto F, Tridello G, De Scolari A, Meneghelli I, Pintani E, Perobelli S, Cipolli M.   +6 more
europepmc   +1 more source

Urticaria multiforme-like eruption due to a novel agent elexacaftor/tezacaftor/ivacaftor in a pediatric patient with cystic fibrosis

JAAD Case Reports, 2021
Rebecca H. Goldberg, BS, Natalie H. Matthews, MD, MPhil, Alexandra C. Hristov, MD, Frank Wang, MD   +3 more
doaj   +1 more source

Long-term impact of elexacaftor/tezacaftor/ivacaftor on small and large airways in people with cystic fibrosis aged ≥6 years: 24-month real-world evidence from the German Cystic Fibrosis Registry. [PDF]

ERJ Open Res
Dillenhöfer S, Schütz K, Burkhart M, Ellemunter H, Kappler M, Sieber S, Naehrlich L, Brinkmann F, Sutharsan S.   +8 more
europepmc   +1 more source

Exposure to CFTR Modulators During Pregnancy in Cystic Fibrosis: Four Cases to Highlight Neonatal Diagnostic Challenges and Outcomes. [PDF]

Int J Neonatal Screen
Domenach L, Pagin A, Cisterne C, Audrezet MP, Couderc L, Monteil L, Roditis L, Murris M, Macey J, Fayon M, Bui S, Reboul MP.   +11 more
europepmc   +1 more source

Comparison of Stool Microbiome in Children with Cystic Fibrosis Treated with and Without Elexacaftor-Tezacaftor-Ivacaftor-A Pilot Study. [PDF]

Int J Mol Sci
Sankararaman S, Liu R, Sun X, Retuerto M, Schindler T, Roesch E, Sferra TJ, Drumm M, Ghannoum M, Zhang L.   +9 more
europepmc   +1 more source

Beyond CFTR: Ivacaftor's role in restoring cellular redox balance and preventing ferroptosis. [PDF]

Redox Biol
Rubin M, Artusi I, Rossetto M, Gucciardi A, Di Paolo ML, Bosello Travain V, Zeppilli D, Orian L, Miotto G, Friedmann Angeli JP, Cozza G.   +10 more
europepmc   +1 more source